MiNK Therapeutics, Inc.
NASDAQ:INKT
0.74 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | -11,708.192 | 0 | 0 | 11,708.192 | 2,704.743 | 1,562.759 | 1,559.312 | 0 | 221.92 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.045 | 0.054 | 0.054 | 5,223.561 | 6,343.344 | 5,854.096 | 0.038 | 7,987.349 | 7,698.431 | 7,374.289 | 0.024 | 13,376.434 | 0 | 0.016 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.045 | -0.054 | -11,708.246 | -5,223.561 | -6,343.344 | 5,854.096 | 2,704.705 | -6,424.59 | -6,139.119 | -7,374.289 | 221.896 | -13,376.434 | 0 | -0.016 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 1 | 0 | 0 | 0.5 | 1 | -4.111 | -3.937 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.84 | 2.549 | 3.311 | 3.427 | 4.558 | 4.194 | 5.812 | 6.15 | 5.876 | 5.277 | 3.95 | 3.334 | 3.585 | 3.098 | 0.788 | 2.504 | 3.109 | 3.109 |
| General & Administrative Expenses
| 1.062 | 1.28 | 2.189 | 1.796 | 1.785 | 1.661 | 2.077 | 1.838 | 1.822 | 2.097 | 2.362 | 0.815 | 0.868 | 0.595 | -0.308 | 0.467 | 0.565 | 0.565 |
| Selling & Marketing Expenses
| -1,060.731 | -1,279.205 | -0.054 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1.017 | 1.227 | 2.135 | 1.796 | 1.785 | 1.661 | 2.077 | 1.838 | 1.822 | 2.097 | 2.362 | 0.815 | 0.868 | 0.595 | -0.308 | 0.467 | 0.565 | 0.565 |
| Other Expenses
| 0.331 | 0 | -0 | 0 | 0 | 0 | -0.015 | 1.563 | 1.559 | -0.402 | 0.549 | -9.592 | -1.078 | 0.59 | -0.369 | -2.433 | 0 | 0 |
| Operating Expenses
| 2.857 | 3.776 | 5.446 | 5.224 | 6.343 | 5.854 | 7.889 | 7.987 | 7.698 | 7.374 | 6.312 | 4.149 | 4.453 | 3.693 | 0.479 | 2.971 | 3.773 | 3.773 |
| Operating Income
| -2.902 | -3.83 | -5.5 | -5.224 | -6.343 | -5.854 | -7.889 | -7.987 | -7.698 | -7.374 | -6.362 | -13.376 | -5.612 | -3.008 | -1.525 | -5.924 | -3.673 | -3.673 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | -0.001 | -0.003 | -0.005 | -0.005 | 0 | -0.029 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.2 | 0.017 | 0.041 | 0 | 6,489.733 | 0.168 | 0.119 | 1.656 | 1.586 | -0.403 | 0.549 | -9.237 | -1.078 | 0.59 | -0.369 | -2.433 | -0.657 | -0.657 |
| Income Before Tax
| -2.702 | -3.813 | -5.459 | -5.116 | -6.197 | -5.686 | -7.77 | -6.332 | -6.113 | -7.777 | -5.764 | -14.267 | -6.335 | -3.846 | -1.535 | -6.043 | -4.33 | -4.33 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | -0 | -0.003 | -0.004 | -0.004 | 0 | -0.026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0 | -0 | -0.107 | 6,489.587 | -168.223 | -0.28 | -1.749 | -1.612 | 0.403 | 0.002 | -8.711 | 0.805 | 1.334 | 0.318 | -1.794 | 0 | 0 |
| Net Income
| -2.702 | -3.813 | -5.459 | -5.116 | -6.197 | 162.537 | -7.49 | -4.583 | -4.501 | -8.18 | -5.764 | -14.267 | -6.335 | -3.846 | -1.535 | -6.043 | -4.33 | -4.33 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0.014 | -0.003 | -0.003 | -0.003 | 0 | -0.026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.073 | -0.11 | -0.16 | -0.15 | -0.18 | 4.79 | -0.22 | -0.14 | -0.13 | -0.24 | -0.18 | -0.43 | -0.22 | -0.14 | -0.054 | -0.21 | -0.18 | -0.18 |
| EPS Diluted
| -0.073 | -0.11 | -0.16 | -0.15 | -0.18 | 4.79 | -0.22 | -0.14 | -0.13 | -0.24 | -0.18 | -0.43 | -0.22 | -0.14 | -0.054 | -0.21 | -0.18 | -0.18 |
| EBITDA
| -2.857 | -3.776 | -5.446 | -5.17 | -6.291 | -5.808 | -7.851 | -7.959 | -7.67 | -7.749 | -5.739 | -13.721 | -4.435 | -3.086 | -0.832 | -5.389 | -3.661 | -3.661 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | -0 | -0.003 | -0.005 | -0.005 | 0 | -0.026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |